Sygnature Discovery, Mironid® Limited, a leader in cell signalling-directed drug discovery and Peak Proteins, have announced they will work closely together to discover new therapies against diseases driven by elevated cyclic AMP (cAMP), such as Autosomal Dominant Polycystic Kidney Disease (ADPKD)....
READ MORE
|
Soliton, a company based in Houston, Texas, has developed an acoustic shockwave device to assist in laser tattoo removal. At present, laser tattoo removal takes a significant number of sessions, with long waits between visits and a significant overall cost. This new device aims to allow numerous laser passes per session, and the company claims that tattoos can be removed in as little as two to three sessions. The acoustic shockwave technology may also be useful for fat and cellulite removal, and...
READ MORE
|
The FDA just approved Epidiolex, the GW Pharma seizure drug derived from cannabis, giving children with two rare and serious forms of epilepsy a new treatment—and companies looking to develop marijuana-based drugs a model for their own path to market. The agency approved Epidiolex, or purified cannabidiol, to treat Lennox-Gastaut syndrome and Dravet syndrome in patients 2 and older. The conditions typically begin in childhood, with frequent or prolonged seizures, and patients have a high r...
FIERCEPHARMA
READ MORE
|
The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ damage and even death. Now, researchers at Penn State have developed a machine learning system that may be able to warn doctors and patients about possible negative side effects that might occur when drugs are mixed. In a study, researchers designed an algorithm that analyzes data on drug-drug interactions listed in reports — ...
READ MORE
|
Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The accelerated approval was based on positive results from the Phase III JAVELIN Renal 101 study, which showed the combination significantly lowered risk of disease progression or death by 31% and extended progression-free survival by 5.4 months for patients with advanc...
READ MORE
|
As a health economist, Karen Van Nuys had heard that it’s sometimes cheaper to pay cash at the pharmacy counter than to put down your insurance card and pay a copay. So one day, she asked her pharmacist how much her prescription would cost if she didn’t use her health coverage and paid cash. “And sure enough, it was [several dollars] below my copay,” Van Nuys said. Van Nuys and her colleagues at the University of Southern California Schaeffer Center for Health Policy &...
KHN.ORG
READ MORE
|